Comparison of the efficacy between the domestic immune
checkpoint inhibitor group and the imported immune checkpoint inhibitor
group
There were 65 patients receiving immunotherapy in this study, all of
whom received PD-1 immune checkpoint inhibitors. Among them, there were
13 patients treated with imported immune checkpoint inhibitors, all of
which were pembrolizumab, and 52 patients treated with domestic immune
checkpoint inhibitors, which were sintilimab and tislelizumab. The
results showed that among the 52 patients treated with domestic immune
checkpoint inhibitors, 17 patients with PD, 32 patients with SD, 3
patients with PR, 3 patients met the criteria for objective response,
and 35 patients met the criteria for for disease control, while among
the 13 patients treated with imported immune checkpoint inhibitors, 4
patients with PD, 8 patients with SD, 1 patient with PR, 1 patient met
the criteria for objective response, and 9 patients met the criteria for
disease control. The results of the different evaluations of the two
groups of patients were statistically analysed separately, and the
results using the Chi-square test and Fisher’s exact test were as
follows: in the case of PD or not, there was no statistical difference
between the two groups, P =0.894; in the case of SD or not, there
was no statistical difference between the two groups,P >0.999; in the case of PR or not, there was no
statistical difference between the two groups, P =0.796; in the
case of objective response or not, there is no statistical difference
between the two groups, P =0.796; in the case of disease control
or not, there is no statistical difference between the two groups,P =0.894, as shown in Table 3. Overall, for patients with treated
metastatic colorectal cancer, there was no difference in the efficacy of
either domestic or imported immune checkpoint inhibitors for treatment.
Table 3 Comparison of efficacy between the domestic ICI group
and the imported ICI group